))
013 Trojan Horse Therapy for Myeloma: A First for the NHS
Manage episode 489858070 series 3655926
Content provided by Dr Jam Kothari & Dr Sally Moore, Dr Jam Kothari, and Dr Sally Moore. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Jam Kothari & Dr Sally Moore, Dr Jam Kothari, and Dr Sally Moore or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Welcome to The Myeloma Minutes.
During this episode, Jam & Sally talk about a ground-breaking new combination therapy for multiple myeloma available on the NHS from this week. They highlight how it works, who it’s for, and what patients need to know.
📌Key Takeaways:
A new 'Trojan horse' drug is now approved on the NHS for first relapse myeloma.
Treatment is effective, flexible — and may only be needed every few months.
Watch out for eye side effects — they're common, but usually temporary and manageable.
This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns
ABOUT YOUR HOSTS
Dr. Jam Kothari
Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr. Sally Moore
Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
13 episodes
Share
